Every row is verified against the original publication
Dosing Retatrutide At a Glance Microdose0.31mg/wk Starts at 0.1 mg for lighter or sensitive microdose-intent profiles, otherwise 0.3 mg
Targeted education and outreach: Inform provider engagement strategies with de-identified real-world data on therapeutic adoption and usage trends
Retatrutide: Injectable Targeting Multiple Receptors Retatrutide, an injectable weight loss drug, targets multiple receptors including GIP, GLP-1, and glucagon receptors, offering a comprehensive approach to weight loss and metabolic health
Some anesthesiologists and gastroenterologists have reported cases of retained gastric contents in certain patients who followed standard pre-procedure fasting instructions while continuing their GLP-1 medications
Even gradual dose escalation does not eliminate intolerance in every patient